Wall Street analyst estimates for Aclaris Therapeutics, Inc. (ACRS): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 13 |
| Hold | 3 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 16 |
| Avg rating (1-5) | 0.81 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-05 | $-0.17 | ||
| 2026-08-06 | $-0.15 | $-0.16 | +6.3% |
| 2026-05-07 | $-0.15 | $-0.16 | +6.3% |
| 2026-02-26 | $-0.16 | $-0.15 | -6.7% |
| 2025-11-06 | $-0.12 | $-0.13 | +7.7% |
| 2025-08-07 | $-0.13 | $-0.13 | +0.0% |
| 2025-05-08 | $-0.12 | $-0.17 | +29.4% |
| 2025-02-27 | $-1.01 | $-0.32 | -215.6% |
Valuation Ratios
| Price / Book | 6.25 |
| EV / EBITDA | -11.22 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | $1.7M | $10.1M | $4.2M | $6.5M | $6.8M | $29.8M | $31.2M | $18.7M | $7.8M |
| Cost of Revenue | $120000 | $1.2M | $6.8M | $4.1M | $5.1M | $4.7M | $12.0M | $18.1M | $2.8M | $2.1M |
| Gross Profit | -$120000 | $476000 | $3.2M | $172000 | $1.3M | $2.0M | $17.8M | $13.2M | $15.9M | $5.7M |
| Research & Development | $33.5M | $39.8M | $63.0M | $64.9M | $29.3M | $43.8M | $77.8M | $98.4M | $33.6M | $52.6M |
| Selling, General & Admin | $15.1M | $33.1M | $75.6M | $27.8M | $20.5M | $23.6M | $25.1M | $31.1M | $22.2M | $22.0M |
| Operating Expenses | $48.6M | $72.9M | $138.7M | $92.7M | $52.3M | $91.8M | $107.6M | $110.5M | $157.9M | $82.1M |
| Operating Income | -$48.6M | -$72.4M | -$135.4M | -$111.1M | -$50.9M | -$89.7M | -$89.9M | -$97.4M | -$141.9M | -$76.4M |
| EBITDA | -$48.6M | -$53.5M | -$80.8M | -$90.2M | -$47.2M | -$64.5M | -$84.4M | -$115.5M | -$51.7M | -$64.5M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$48.1M | -$70.4M | -$132.7M | -$113.5M | -$51.3M | -$90.9M | -$86.9M | -$88.8M | -$132.1M | -$64.9M |
| Income Tax | -$120000 | -$1.8M | $2.7M | 0 | -$182000 | 0 | 0 | -$367000 | 0 | 0 |
| Net Income | -$48.1M | -$68.5M | -$132.7M | -$161.4M | -$51.0M | -$90.9M | -$86.9M | -$88.5M | -$132.1M | -$64.9M |
| EPS | $-2.25 | $-2.44 | $-4.03 | $-3.46 | $-1.20 | $-1.60 | $-1.33 | $-1.27 | $-1.71 | $-0.53 |
| EPS (Diluted) | $-2.25 | $-2.44 | $-4.03 | $-3.46 | $-1.20 | $-1.60 | $-1.33 | $-1.27 | $-1.71 | $-0.53 |
| Shares Outstanding (Diluted) | $21.4M | $28.1M | $32.9M | $41.3M | $42.5M | $56.7M | $65.2M | $69.8M | $77.3M | $122.7M |
Price
| Price | $5.32 |
| Market Cap | $743M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ALLO · BIOA · CABA · EDIT · MASS · MDXH · NEO
Explore sector: Healthcare · Biotechnology
More sections of ACRS: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks